Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Seattle Genetics, Inc.

Bayer Schering Pharma Ag

Mark Jean Gnoth

Johannes-Peter Stasch

Elisabeth Perzborn

Susanne Röhrig

Philip Lienau

Christoph Gerdes

Stefan Heitmeier

Ulf Bömer

Knut Eis

Arne Scholz

Gerhard Siemeister

Adrian Tersteegen

Anja Buchmüller

Andreas Wilmen

Niels Svenstrup

Katja Zimmermann

Mario Jeske

Yolanda Cancho Grande

Ludwig Zorn

Judith Günther

Marcus Bauser

Dmitry Zubov

Marion Hitchcock

Dieter Lang

Rolf Bohlmann

Hans Briem

Dirk Kosemund

Ulrich Lücking

Anne Mengel

Hartmut Schirok

Simon Holton

Antje Margret Wengner

Volker Schulze

Michael Sperzel

Amaury Ernesto Fernandez-Montalvan

Klaus Münter

Joachim Schuhmacher

Hans-Georg Lerchen

Joachim Mittendorf

Raimund Kast

Beatrix Stelte-Ludwig

Christoph-Stephan Hilger

Ursula Krenz

Ulrich Rester

Stephan Siegel

Dirk Heimbach

Kersten Matthias Gericke

Georges Von Degenfeld

Eckhard Bender

Swen Allerheiligen

Michael Gerisch

Elke Dittrich-Wengenroth

Jörg Fanghänel

Stefan Prechtl

Carsten Schultz-Fademrecht

Gerd Rühter

Vera Pütter

Dirk Schneider

Mark Meininghaus

Florian Puehler

Florian Pühler

Daniel Korr

Jochen Strayle

Uwe Saatman

Michael Härter

Sherif El Sheikh

Holger Paulsen

Christian Stegmann

Gerd Ruhter

Joachim Krüger

Martin Radtke

Samir Bennabi

Sven Golfier

Uwe Saatmann

Cornelia Preusse

Santiago Figueroa Perez

Anja Richter

Julia Straβburger

Julia Strassburger

Michael Thutewohl

Cornelia Preuβe

Heimo Ehmke

Carsten Schulz-Fademrecht

Amaury Ernesto Fernández-Montalván

Georges Degenfeld

Ulrich Lucking

Ulf BÖMER

Florian PÜHLER

Jörg FANGHÄNEL

Jochen Stayle

Dimitry Zubov

Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.

Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases

Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases

The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).

4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group

The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted aminoimidazopyridazines

The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia). 

Compounds of formula (I) and their use as pharmaceutical. 

Substituted benzylpyrazoles

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R3 and n are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amino-substituted imidazopyridazines

The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.

Imidazo-, pyrazolopyrazines and imidazotriazines and their use

The present invention relates to substituted imidazopyridazine compounds of general formula (I): in which A, Q, R1, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted imidazopyridazines

The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Heterocyclyl aminoimidazopyridazines

The invention relates to substituted imidazo- and triazolopyrimidines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of haematological disorders, preferably of leucopenias and neutropenias.

Substituted imidazopyrimidines and triazolopyrimidines

The present application relates to new derivatives, substituted on the N terminus by a carboxyalkyl group, of monomethylauristatin E and monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and to the use of these derivatives for producing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments may be applied as a monotherapy or else in combination with other medicaments or further therapeutic measures.

N-carboxyalkylauristatins and use thereof

The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumor disorders.

Substituted piperidines as Par-1 antagonists

The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines

The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

Substituted oxazolidinones and their use

Growing community of inventors

Mettmann, Germany

Mark Jean Gnoth